High Potency Active Pharmaceutical Ingredients Market - Global Industry Analysis, Size, Growth, Share And Forecast, 2012 - 2018

In this research report Transparency Market Research analyzes the global high-potency active pharmaceutical ingredients market (HPAPI) along with market dynamics and present market condition. It also covers the market of high-potency active pharmaceutical ingredients types and application in different regions of the world namely, North America, Europe, Asia and RoW along with their sub segments. Moreover, the report provides detailed and in-depth analysis of the HPAPI market, with their estimated figures and forecast from 2012 to 2018, along with compound annual growth rate from 2012 to 2018.

The global high-potency active pharmaceutical ingredients market has shown favorable growth trend in the last few years and is expected to grow rapidly in the forecasted period. The demand of oncology products is further expected to drive the growth of this market. The high level of competition in this market is due to new entrants fragmenting the market. HPAPI market by type of synthesis has been covered in this report providing their estimates and forecast from 2012 to 2018. The drivers, restraints and opportunities have also been covered broadly in this report along with their impact analysis. These market dynamics will be highly helpful in taking corporate decisions related to the HPAPI market.

High potency active pharmaceutical ingredients (HPAPIs) are growing rapidly as compared to other segments of the healthcare industry. HPAPI are the compounds helpful in the treatment of respiratory disorders, treatment of cancer and hormonal imbalances. Growing oncology therapeutics market worldwide is the key factor driving the growth of this market.

High Potency Active Pharmaceutical Ingredients Market is a growing concept and is considered to be a boost to the pharmaceutical industry. Patented high potency drug development majorly dominates the HPAPI market. The branded sector constitutes the major share of this market but the patents of this branded sector are expected to expire in the coming few years that will help HPAPI manufacturers to cater to multiple clients by producing the generic version of the ingredients in bulk.

Some of the factors driving this market at a rapid growth rate are majority of blockbuster drugs nearing patent expiry, US government promoting generic drugs to reduce its medical burden, insurance companies preferring generic drugs over patented drugs for cost effectiveness and India and China with maximum DMFs with the US FDA.

However, a large number of competitors are entering this market making it highly fragmented which may slow down the growth of this market. Moreover, reduced R&D investments leading to low demand of HPAPIs and shortage of US FDA approved manufacturing sites are also likely to be the major restraints for the growth of the high potency active pharmaceutical ingredients market.

However, North America has been the largest market for high potency pharmaceutical ingredients as the country spends highly on the development of healthcare systems, whereas the European market has experienced several fluctuations in the past few years but is expected to grow rapidly in the near future due to rise in the demand of oncology drugs in this region.

Browse Report : http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

Read More

Seasonal Influenza Vaccines Industry In Top Seven Countries To 2018 - Next Generation Quadrivalent Vaccines To Dominate The Market By Offering Broader Protection Via Single Dose

GBI Research, the leading business intelligence provider, has released its latest research, Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose, which provides essential insights into seasonal influenza vaccines sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2018. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes insights into the seasonal influenza vaccine R&D pipeline and gives profiles of promising vaccines, as well as exploring the competitive landscape through profiles for the top companies. Key trends in terms of M&A and licensing agreements are also analyzed.

Browse Report : Seasonal Influenza Vaccines Market In Top Seven Countries To 2018

GBI Research expects the market to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the 20112018 period from $2.9 billion in 2011 to $3.8 billion by 2018, driven by growing awareness, increasing vaccination coverage and rising government support for immunization against seasonal influenza. On the other hand, limited production capacity, high investment and strict regulations may act as barriers to entry.

The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $1.6 billion in 2011 to $2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germanys market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $385.5m to $465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.

GBI Researchs analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. The market is currently dominated by trivalent vaccines but will witness the launch of quadrivalent vaccines in the near future.

Read More : Seasonal Influenza Vaccines Industry

Scope

• Data and analysis on the seasonal influenza vaccine market in the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan
• Market forecasts for seasonal influenza vaccines until 2018
• Market data on geographical landscape in terms of country, vaccination coverage, public and private contribution to the total number of doses, vaccine price and market size
• Key drivers and restraints that have had a significant impact on the market
• Regulatory landscape, including the approval process and an overview of the regulatory authorities in the top seven countries
• Competitive landscape of the seasonal influenza vaccine market in the top seven countries including top companies profiles, namely Sanofi, Johnson & Johnson, GlaxoSmithKline Biologicals, Novartis Vaccines and AstraZeneca
• Key M&A activities and licensing agreements that have taken place between 2009 and mid-2012

Reasons to buy

• Build effective strategies to launch pipeline products by identifying potential geographies
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
• Develop key strategic initiatives by studying top competitors key strategies
• Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
• Reinforce R&D pipelines by identifying new target mechanisms able to produce safer and more efficacious first-in-class vaccines

Browse : http://www.businessresearchindustry.com/report/seasonal-influenza-vaccines-market-in-top-seven-countries-to-2018-next-generation-quadrivalent-vaccines-to-dominate-the-market-by-offering-broader-protection-via-single-dose.htm

Read More

Gastrointestinal Disorders Therapeutics Industry To 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) And Ulcerative Colitis (UC) To Reinvigorate The Market

GBI Research, the leading business intelligence provider, has released its latest research, Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market, which provides insights into the gastrointestinal disorders therapeutics market until 2018. 

Browse : Gastrointestinal Disorders Therapeutics Industry

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. It provides in-depth analysis of the major diseases, comprising IBS, constipation, Crohns disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

GBI Researchs analysis shows that the gastrointestinal disorders therapeutics market is set to witness high generic competition in the forecast period, as major drugs used in the treatment of the aforementioned disorders are set to expire, resulting in declining revenues and allowing generics to enter the market. Nevertheless, the market will witness steady growth due to the anticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS, constipation, Crohns disease and UC remains a key market driver.

Scope

• Data and analysis for the gastrointestinal disorders therapeutics markets in the leading geographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italy and Spain; Japan; and an overview of India, China and Australia
• Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010 and forecast to 2018
• Market data for the geographical and therapeutic landscapes, including size, share, annual cost of therapy, sales volume and treatment usage patterns for the diseased population, diagnosis population and prescription population
• Generic share in the global market and for each indication
• Key drivers and restraints that have had a significant impact on the market
• The competitive landscape of the global market, looking at key companies such as AstraZeneca, Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix
• Key M&A activity and licensing agreements that took place between 2010 and 2012

Read Report : Gastrointestinal Disorders Therapeutics Market To 2018 

Reasons to buy

• Align product portfolios to the markets with high growth potential
• Build effective strategies to launch pipeline products by identifying potential geographies
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
• Develop key strategic initiatives by studying top competitors key strategies
• Device a more tailored country strategy by understanding the key drivers, barriers and market potential for each indication
• Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
• Reinforce R&D pipelines by identifying new target mechanisms producing safer and more efficacious FIC molecules

Browse : http://www.businessresearchindustry.com/report/gastrointestinal-disorders-therapeutics-market-to-2018-novel-agents-targeting-irritable-bowel-syndrome-ibs-chronic-constipation-cc-and-ulcerative-colitis-uc-to-reinvigorate-the-market.htm

Read More

Downstream Processing Market In Biopharmaceuticals - Adoption Of Disposable Technology At Improved Economies Of Scale To Optimize Production Efficiency And Cost-Effectiveness

GBI Research, the leading business intelligence provider, has released its latest research, Downstream Processing in Biopharmaceuticals Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness, which provides key data, information and analysis of the Contract Manufacturing Organization (CMO) industry, and the downstream processing and reagent market. 

Browse: Downstream Processing Market

The report provides comprehensive insight into the size of the CMO market, the downstream processing and reagent market and includes forecasts, key reasons for outsourcing, market characterization, downstream process in biopharmaceuticals, major reagents, reagent suppliers and the reagent market related to downstream processing, profiles of key equipment players, key reagent players and key CMO players, drivers and restraints and deals analysis.

This report is built using data and information sourced from proprietary databases, primary and secondary research and uses in-house analysis from GBI Researchs team of industry experts.

Major CMOs offer both upstream and downstream manufacturing functions equally. In addition to manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing. According to industry experts, almost 60% of the CMO market in dominated by manufacturing functions, out of which more than 50% is dominated by the downstream process. GBI research suggests that the CMO market size for downstream processing is set to grow at a Compound Annual Growth Rate (CAGR) of 15.1%, which is more than the growth in the overall CMO biopharmaceutical market.

Browse Report : Downstream Processing Market In Biopharmaceuticals

Scope

• A detailed overview of the downstream processing, CMO industry and reagent market.
• Annualized market data and forecasts for the downstream processing, CMO industry and reagent market.
• A detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers and restraints of the market.
• A detailed discussion of the downstream processing.
• Company profiles of major equipments suppliers, CMOs and reagent players including the key services offered by them and their financial information. 
• Analysis of the Merger and Acquisition (M&A) deals involving key companies

Reasons to buy

• Develop market-entry and market expansion strategies by identifying areas for high growth and opportunities.
• Understand the factors shaping the downstream processing, CMO industry and reagent market.
• Identify the top players in the major equipment suppliers, CMO and reagent market, their financial revenues, geographical presence and key services offered. 
• Analyze the key geographies that are lucrative markets for the downstream processing and as well as CMOs.
• Analyze the trends in licensing and M&A deals and explore potential investment opportunities
• Understand upcoming trends that are poised to drive the future growth of the downstream processing

Browse : http://www.businessresearchindustry.com/report/downstream-processing-in-biopharmaceuticals-adoption-of-disposable-technology-at-improved-economies-of-scale-to-optimize-production-efficiency-and-cost-effectiveness.htm

Read More

Leukemia Therapeutics Industry To 2018 - Strong Late-Stage Pipeline To Sustain Branded Drugs' Major Market Share

GBI Research, the leading business intelligence provider, has released its latest research Leukemia Therapeutics Market to 2018 Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share which provides insights into leukemia therapeutics market until 2018 for four major indications. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. 

Browse : Leukemia Therapeutics Industry To 2018

The report provides an in-depth analysis of the major leukemia indications including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML) and chronic myelocytic leukemia (CML). The report examines the global leukemia diseases treatment usage patterns. In addition, the geographical distribution of leukemia therapeutics and markets across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the leukemia therapeutics R&D product pipeline and explores the competitive landscape including major players in the leukemia therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in leukemia therapeutics market.

In 2011, the leukemia therapeutics market for four major leukemia indications was estimated at $4.0 billion, indicating a compound annual growth rate (CAGR) of 21.0% since 2004. GBI Research forecasts the market to grow at a CAGR of 9.5% between 2011 and 2018 to reach to $7.6 billion by 2018. The four indications covered are treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). The historic growth in major markets such as the US, the top five countries of Europe and Japan were driven mainly by the increasing prevalence and prescription population as well as launch of newer brands such as Sprycel, Tasigna, Clolar and Arranon with no major patent expirations. The US was the leading market with an estimated sales value of $1.8 billion in 2011 and an approximate share of 44.3%. The US market is expected to grow at a CAGR of 10.0% between 2011 and 2018 to record sales value of $3.5 billion in 2018. The top five countries of Europe together contributed to sales worth $1.5 billion in 2011, accounting for an approximate share of 37.9%. The top five countries of Europe are expected to record sales worth $3.1 billion by the year 2018, at a CAGR of 10.3%. Japan, in 2011, contributed $720m to the global market increasing at a CAGR of 20.8% from 2004. It accounts for an approximate share of 17.8%. Growing at a CAGR of 6.1% between 2011 and 2018, the market is expected to record sales worth $1.1 billion by 2018.

Browse : Leukemia Therapeutics Market

Scope

• Data and analysis on the leukemia therapeutics market in the leading geographies of the world the US, Japan, the UK, Germany, France, Italy and Spain 
• Annualized market data for the leukemia therapeutics market from 2004 to 2011, with forecasts to 2018
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population
• Key drivers and restraints that have had a significant impact on the market
• The competitive landscape of the global leukemia therapeutics market including top companies benchmarking. The key companies studied in this report are Novartis AG, GlaxoSmithKline plc (GSK), Genzyme Corporation, Bristol-Myers Squibb Company (BMS) and Eisai Co., Ltd.
• Key M&A activities and licensing agreements that took place in 2009 and 2011 in the leukemia therapeutics market.

Reasons to buy

• Align your product portfolio to the markets with high growth potential. 
• Build effective strategies to launch their pipeline products by identifying potential geographies. 
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps. 
• Develop key strategic initiatives by studying the key strategies of top competitors. 
• Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication. 
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth. 
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Browse Report : http://www.businessresearchindustry.com/report/leukemia-therapeutics-market-to-2018-strong-late-stage-pipeline-to-sustain-branded-drugs-major-market-share.htm

Read More